General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Bayer Inc.
Indication:
Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Last updated December 30, 2019
Lutathera (lutetium 177 dotatate)
Status:
Concluded without agreement
Manufacturer:
Advanced Accelerator Applications
Indication:
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Last updated December 30, 2019
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Cytomegalovirus infection prophylaxis
Last updated December 18, 2019
Status:
Negotiations were not pursued
Manufacturer:
Merck Canada Inc.
Indication:
Metastatic Urothelial Carcinoma (first line)
Last updated November 29, 2019
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Psoriasis, moderate to severe plaque
Last updated November 28, 2019
Status:
Concluded with an LOI
Manufacturer:
AVIR Pharma Inc.
Indication:
Invasive aspergillosis and mucormycosis
Last updated November 25, 2019
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Multiple Sclerosis, Relapsing
Last updated November 22, 2019
Dovato (dolutegravir/lamivudine)
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated November 21, 2019
Soliqua (lixisenatide/insulin glargine)
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated November 21, 2019
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated November 21, 2019